½ÃÀ庸°í¼­
»óǰÄÚµå
1601307

ÀÚ±â ÁÖ»ç ½ÃÀå : À¯Çü, ¿ëµµ, À¯Åë ä³Î, Ä¡·á ºÐ¾ß ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÚ±â ÁÖ»ç ½ÃÀåÀº 2023³â 540¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 606¾ï 4,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 12.72%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1,248¾ï 7,000¸¸ ´Þ·¯¿¡ µµ´Þ ¿¹ÃøµË´Ï´Ù.

ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀå¿¡´Â ȯÀÚ°¡ Àü¹®°¡ÀÇ µµ¿ò¾øÀÌ ÇÇÇÏ¿¡¼­ ¾à¹°À» Åõ¿© ÇÒ ¼öÀÖ°ÔÇÏ´Â Àåºñ¿Í ±â¼úÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Á߽à Áõ°¡ÇÏ°í ºñ¿ë È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿äÀÔ´Ï´Ù.ÀÚ°¡ ÁÖ»çÁ¦´Â ´ç´¢º´, ·ù¸¶Æ¼½º °üÀý¿°, ´Ù¹ß¼º °æÈ­Áõ µîÀÇ Áúº´ °ü¸®¿¡ ÇÊ¿äÇϸç ȯÀÚ¿¡°Ô ÀÚÀ²¼ºÀ» Á¦°øÇÏ¸ç ¿Ü·¡ ȯÀÚ °ü¸®¿¡ ½Ã ¹ß¿¡ ºÎÇÕÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¼¼°è ³ëÀÎ Àα¸ Áõ°¡, »ý¹° Á¦Á¦ÀÇ Áøº¸, ÁÖ»ç ±â±¸ÀÇ »ç¿ë¼º Çâ»ó µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Ç÷§ÆûÀ» ÅëÇÕÇÑ ½º¸¶Æ® ÀÚ°¡ÁÖ»ç ½Ã½ºÅÛ °³¹ß°ú ¸¸¼ºÁúȯÀÌ ±ÞÁõÇϰí ÀÖ´Â ½ÅÈï±¹ ½ÃÀåÀ» À§ÇÑ Á¦Ç° Àü°³¿¡ ºñÁî´Ï½º ±âȸ°¡ Á¸Àç ±×·¯³ª °íµµÀÇ ÀÚ°¡ÁÖ»ç ½Ã½ºÅÛÀÇ °í°¡ÀÇ ºñ¿ë, Àú°³¹ß Áö¿ª¿¡¼­ÀÇ ÀÎÁöµµ ºÎÁ·, ȯÀÚÀÇ ÁÖ»ç ¹Ù´Ã¿¡ ´ëÇÑ ºÒ¾È µîÀÇ °úÁ¦°¡ ä¿ë·üÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. °ú »óȯ Á¤Ã¥ÀÇ ÆíÂ÷µµ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¡ ´ëÀÀÇϴ ȯÀÚ Áß½ÉÀÇ Çõ½Å¿¡ ÅõÀÚÇÔÀ¸·Î½á ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ±³À° ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃßÁøÇÏ´Â ÀÇ·á Á¦°ø¾÷ü¿ÍÀÇ Á¦È޴ ȯÀÚÀÇ ½Å·Ú¿Í ÄÄÇöóÀ̾𽺸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.½ÃÀåÀº ´ÙÀ̳ª¹ÍÇÏÁö¸¸ ´ÜÆíÈ­µÇ¾î ÀÖ¾î ±â¼úÀû ¿ìÀ§¼ºÀ» Ãß±¸ÇÏ´Â ¿©·¯ ÁÖ¿ä ±â¾÷ÀÌ Á¸ÀçÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. °ß°íÇÑ ½ÃÆÇ ÈÄ Á¶»ç½Ã ½ºÅÛ¿¡ ÁßÁ¡À» µÐ ÀÌ´Ï¼ÅÆ¼ºê´Â Àü¹ÝÀûÀ¸·Î ÀÚ°¡ÁÖ»ç ½ÃÀåÀº ƯÈ÷ °Ç°­ ÁöÇâÀû ÀÎ ¼¼°è Àα¸¿¡ ´ëÀÀÇÏ´Â Àü·«Àû Á¦ÈÞ¿Í ±â¼ú Áøº¸¸¦ ÅëÇØ Çõ½Å Áß½ÉÀÇ ¼ºÀåÀ» ±â´ëÇÒ ¼öÀÖ´Â À¯¸ÁÇÑ ½ÃÀåÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 540¾ï ´Þ·¯
¿¹Ãø³â(2024) 606¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 1,248¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 12.72%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÀÚ°¡ÁÖ»çÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÚ±â ÁÖ»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º Áúȯ ¹× ·ù¸¶Æ¼½º °üÀý¿°ÀÇ ±Þ¼ÓÇÑ À¯Çà
    • ºÒÀÓ Ä¡·á¿¡¼­ ÀÚ°¡ÁÖ»çÁ¦ÀÇ ±¤¹üÀ§ÇÑ ÀÌ¿ë °¡´É¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç° ȸ¼öÀÇ ÀáÀçÀû À§Çè
  • ½ÃÀå ±âȸ
    • ¼¼°è¿¡¼­ ÀÚ±â ÁÖ»çÀÇ Á¤ºÎ ½ÂÀÎÀÌ °è¼ÓÁß
    • ÀÚ°¡ÁÖ»ç ÀåÄ¡ÀÇ ±â¼úÀû Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ÀÚ°¡ÁÖ»çÁ¦¿¡ °üÇÑ ÀÎÁöµµÀÇ ³·À½°ú °ü¸®»óÀÇ °úÁ¦

Porter's Five Forces : ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. Äí´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇÇÇÒ ¼ö ÀÖÀ¸¸ç ´õ °­ÀÎÇÑ ½ÃÀå Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹ÃøÇÒ ¼ö ÀÖ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÚü ÁÖ»ç ¾à¹° ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °ø°³ ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÚ°¡ÁÖ»ç ¾à¹° ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÚü ÁÖ»ç ¾à¹° ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¿¡ µû¶ó °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÚ±â ÁÖ»ç ½ÃÀå : À¯Çüº°

  • ÀÚµ¿ ÁÖ»ç±â
  • ¹«Ä§ ÁÖ»ç±â
  • ÆæÇü ÁÖ»ç±â
  • ¿þ¾î·¯ºí ÀÎÁ§ÅÍ

Á¦7Àå ÀÚ±â ÁÖ»ç ½ÃÀå : ¿ëµµº°

  • ÀÏȸ¿ë
  • Àç»ç¿ë °¡´É

Á¦8Àå ÀÚ±â ÁÖ»ç ½ÃÀå : À¯Åëä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • °³ÀΠŬ¸®´Ð

Á¦9Àå ÀÚ±â ÁÖ»ç ½ÃÀå " Ä¡·á ¿µ¿ªº°

  • ÀÚ°¡¸é¿ªÁúȯ
    • ¿¡ÀÌÁî
    • ¾Ë·¹¸£±â
    • ¾Ï
    • °ú¹Î¼º ÀåÀå¾Ö
    • ´Ù¹ß¼º °æÈ­Áõ
    • °Ç¼±
  • ±ä±Þ ÀǾàǰ
    • ¾Æ³ªÇʶô½Ã ¾ç¸»
    • ÆíµÎÅë
  • È£¸£¸ó º¸Ãæ ¿ä¹ý
    • º£Å¸ ÀÎÅÍÆä·Ð
    • ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾
    • ³­Æ÷ ÀÚ±Ø È£¸£¸ó
    • ÇìÆÄ¸°
    • Àν¶¸°
    • ºÎ°©»ó¼± È£¸£¸ó
    • ÆÄŲ½¼º´

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÚ±â ÁÖ»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚ±â ÁÖ»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚ±â ÁÖ»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸ñ·Ï

  • Insulet Corporation
  • Johnson & Johnson Services, Inc.
  • SCHOTT AG
  • Eli Lilly and Company
  • AstraZeneca plc
  • PharmaJet, Inc.
  • West Pharmaceutical Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Terumo Corporation
  • Enable Injections, Inc.
  • Owen Mumford Limited
  • SHL Medical AG
  • Merck KGaA
  • Sanofi SA
  • Recipharm AB
  • DALI Medical Devices Ltd.
  • Credence MedSystems, Inc.
  • Novo Nordisk A/S
  • Mylan NV by Viatris Inc.
  • GlaxoSmithKline plc
  • Gerresheimer AG
  • Medmix AG by Sulzer Ltd.
  • Molex LLC by Koch Industries, Inc.
  • PenJet Corporation
  • Ypsomed Group
  • Baxter International, Inc.
  • Pfizer Inc.
  • Becton, Dickinson and Company
  • Antares Pharma, Inc. by Halozyme, Inc.
  • AbbVie Inc.
BJH 24.12.06

The Self-injections Market was valued at USD 54.00 billion in 2023, expected to reach USD 60.64 billion in 2024, and is projected to grow at a CAGR of 12.72%, to USD 124.87 billion by 2030.

The self-injections market encompasses devices and technologies that enable patients to administer medications subcutaneously without professional assistance. This market is driven by increased chronic disease prevalence, a growing emphasis on home healthcare, and the demand for cost-effective medical treatments. Self-injections are necessary for managing conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis, providing patients with autonomy and aligning with the shift towards outpatient care. Key influencers of market growth include the rising global geriatric population, advances in biologics, and improved usability of injection devices. Opportunities exist in the development of smart self-injection systems that integrate digital health platforms for real-time monitoring and adherence, as well as expanding offerings for emerging markets where chronic diseases are rising rapidly. However, challenges such as high costs of advanced self-injection systems, lack of awareness in underdeveloped regions, and patients' needle anxiety may impede adoption rates. Additionally, regulatory hurdles and variability in reimbursement policies pose significant barriers. Companies can foster growth by investing in patient-centric innovations, such as needle-free injectors and user-friendly app-assisted devices, that break conventional boundaries and cater to specific patient needs. Research into pain-free delivery technologies and enhanced training modules for first-time users could revolutionize the market landscape. Partnerships with healthcare providers to promote educational initiatives can also improve patient confidence and compliance. The market is dynamic but fragmented, characterized by several key players striving for technological superiority. Enhanced focus on sustainable manufacturing processes and robust post-market surveillance systems will be vital as companies align themselves with evolving environmental policies and regulations. Overall, the self-injection market holds promising potential for innovation-led growth, particularly through strategic collaborations and technological advancements that cater to an increasingly health-conscious global population.

KEY MARKET STATISTICS
Base Year [2023] USD 54.00 billion
Estimated Year [2024] USD 60.64 billion
Forecast Year [2030] USD 124.87 billion
CAGR (%) 12.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Self-injections Market

The Self-injections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid prevalence of chronic diseases and rheumatoid arthritis
    • Wide availability of self-injections for fertility treatments
  • Market Restraints
    • Potential risk of product recall
  • Market Opportunities
    • Ongoing government approvals for self-injections worldwide
    • Technological advancements in self-injection devices
  • Market Challenges
    • Limited awareness and administration challenges associated with self-injections

Porter's Five Forces: A Strategic Tool for Navigating the Self-injections Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Self-injections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Self-injections Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Self-injections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Self-injections Market

A detailed market share analysis in the Self-injections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Self-injections Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Self-injections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include Insulet Corporation, Johnson & Johnson Services, Inc., SCHOTT AG, Eli Lilly and Company, AstraZeneca plc, PharmaJet, Inc., West Pharmaceutical Services, Inc., Teva Pharmaceutical Industries Ltd., Terumo Corporation, Enable Injections, Inc., Owen Mumford Limited, SHL Medical AG, Merck KGaA, Sanofi S.A., Recipharm AB, DALI Medical Devices Ltd., Credence MedSystems, Inc., Novo Nordisk A/S, Mylan N.V. by Viatris Inc., GlaxoSmithKline plc, Gerresheimer AG, Medmix AG by Sulzer Ltd., Molex LLC by Koch Industries, Inc., PenJet Corporation, Ypsomed Group, Baxter International, Inc., Pfizer Inc., Becton, Dickinson and Company, Antares Pharma, Inc. by Halozyme, Inc., and AbbVie Inc..

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Auto-Injectors, Needle-free Injectors, Pen Injectors, and Wearable Injectors.
  • Based on Usage, market is studied across Disposable and Reusable.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Private Clinics.
  • Based on Therapeutic Areas Application, market is studied across Autoimmune Diseases, Emergency Drugs, and Hormone Replacement Therapies. The Autoimmune Diseases is further studied across AIDS, Allergies, Cancer, Irritable Bowel Disorders, Multiple Sclerosis, and Psoriasis. The Emergency Drugs is further studied across Anaphylactic Socks and Migraine. The Hormone Replacement Therapies is further studied across Beta-Interferon, Erythropoietin, Follicle Stimulating Hormone, Heparin, Insulin, Parathyroid Hormone, and Parkinson's.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
      • 5.1.1.2. Wide availability of self-injections for fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing government approvals for self-injections worldwide
      • 5.1.3.2. Technological advancements in self-injection devices
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and administration challenges associated with self-injections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
    • 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
    • 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
    • 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Self-injections Market, by Type

  • 6.1. Introduction
  • 6.2. Auto-Injectors
  • 6.3. Needle-free Injectors
  • 6.4. Pen Injectors
  • 6.5. Wearable Injectors

7. Self-injections Market, by Usage

  • 7.1. Introduction
  • 7.2. Disposable
  • 7.3. Reusable

8. Self-injections Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
    • 9.2.1. AIDS
    • 9.2.2. Allergies
    • 9.2.3. Cancer
    • 9.2.4. Irritable Bowel Disorders
    • 9.2.5. Multiple Sclerosis
    • 9.2.6. Psoriasis
  • 9.3. Emergency Drugs
    • 9.3.1. Anaphylactic Socks
    • 9.3.2. Migraine
  • 9.4. Hormone Replacement Therapies
    • 9.4.1. Beta-Interferon
    • 9.4.2. Erythropoietin
    • 9.4.3. Follicle Stimulating Hormone
    • 9.4.4. Heparin
    • 9.4.5. Insulin
    • 9.4.6. Parathyroid Hormone
    • 9.4.7. Parkinson's

10. Americas Self-injections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Self-injections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
    • 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
    • 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
    • 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
    • 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
    • 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
    • 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
    • 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
    • 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
    • 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

Companies Mentioned

  • 1. Insulet Corporation
  • 2. Johnson & Johnson Services, Inc.
  • 3. SCHOTT AG
  • 4. Eli Lilly and Company
  • 5. AstraZeneca plc
  • 6. PharmaJet, Inc.
  • 7. West Pharmaceutical Services, Inc.
  • 8. Teva Pharmaceutical Industries Ltd.
  • 9. Terumo Corporation
  • 10. Enable Injections, Inc.
  • 11. Owen Mumford Limited
  • 12. SHL Medical AG
  • 13. Merck KGaA
  • 14. Sanofi S.A.
  • 15. Recipharm AB
  • 16. DALI Medical Devices Ltd.
  • 17. Credence MedSystems, Inc.
  • 18. Novo Nordisk A/S
  • 19. Mylan N.V. by Viatris Inc.
  • 20. GlaxoSmithKline plc
  • 21. Gerresheimer AG
  • 22. Medmix AG by Sulzer Ltd.
  • 23. Molex LLC by Koch Industries, Inc.
  • 24. PenJet Corporation
  • 25. Ypsomed Group
  • 26. Baxter International, Inc.
  • 27. Pfizer Inc.
  • 28. Becton, Dickinson and Company
  • 29. Antares Pharma, Inc. by Halozyme, Inc.
  • 30. AbbVie Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦